ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31

ABEONA THERAPEUTICS INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$4.41−0.02 (-0.45%)

Close on Oct 19, 2026

Market cap: $251.58M
P/E (TTM): –
Dividend yield: –

ABEONA THERAPEUTICS INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Depreciation & Amortization	2.55	2.00	2.29	3.09	3.25	4.59	7.82	2.36	0.74	0.83	0.55	0.01	0.00	0.42	0.23	0.24
Stock-Based Compensation	11	6.63	4.77	3.05	8.92	5.85	7.34	8.18	4.64	4.83	4.37	1.31	0.44	0.39	1.07	1.02
Other Non-Cash Items	–	–	–	–	–	-0.35	-0.37	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	-6.15	–	–	3.00	-3.00	–	0.08	0.03	0.02	-0.01	-0.08	0.04	0.77	-0.51	0.69	-0.98
Change in Inventory	-5.49	–	–	–	–	–	–	–	–	–	–	0	0.19	-0.04	-0.15	–
Change in Accounts Payable	6.54	1.51	2.04	-4.11	0.83	–	–	7.67	-1.30	2.82	-1.17	0.03	-1.18	0.57	0.05	-0.60
Change in Unearned Revenue	–	–	–	-0.29	–	–	–	0.30	2.01	-0.60	-0.60	-0.35	2.87	-0.60	-1.18	-0.35
Operating Cash Flow	-76	-56	-37	-43	-66	-35	-63	-39	-23	-13	-10	-1.61	0.00	-3.96	-7.61	-6.86
Capital Expenditures	-7.98	-2.45	-0.33	-0.13	-4.15	-1.34	-6.31	-9.24	-0.86	-0.52	-0.31	0	0.00	-0.01	-0.04	-0.01
Sale of Property, Plant & Equipment	–	0.02	0.20	1.73	–	–	–	–	–	0	3.70	0	–	–	–	–
Purchase of Investments	-207	-157	-52	-78	-20	-170	–	-136	0	0	–	–	–	–	–	–
Sale & Maturity of Investments	152	–	–	–	–	–	–	71	0	0	–	–	–	–	–	–
Investing Cash Flow	105	-39	0.21	-24	66	-84	60	-85	-0.86	-0.52	3.39	0	0.00	-0.01	-0.04	-0.01
Stock Issued	17	15	14	13	8.05	–	17	–	–	–	7.00	0	0	–	5.83	13
Debt Issued	–	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	26	104	37	43	25	1.94	114	5.48	92	43	36	13	0.03	1.90	3.08	13
Net Change in Cash	55	8.88	0.26	-24	25	-117	111	-119	69	29	29	11	0.03	-2.06	-4.57	6.43
Free Cash Flow	-84	-58	-37	-44	-70	-36	-69	-48	-24	-14	-11	-1.61	0.00	-3.97	-7.65	-6.87
Income Taxes Paid	–	0.01	0.01	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest Paid	2.59	2.67	–	–	–	–	–	0.01	0.01	0.01	0.01	0.01	0	0.39	0.72	-0.87

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 67.1%
Operating margin: -327.6%
Net margin: -246.4%
Return on equity, FY2025: 70.0%

Financial strength

Current ratio: 6.63
Debt to equity: 0.12
Debt to assets: 8.3%
Cash to current liabilities: 226.7%

Valuation

P/E ratio: –
Price to sales: 9.86
Price to book: 1.96
Dividend yield: –